Last updated on November 2019

Extension Study for the Port Delivery System With Ranibizumab (Portal)

Brief description of study

This study will evaluate the long-term safety and tolerability of the Port Delivery System (PDS) with ranibizumab 100 mg/mL with refills administered every 24 weeks (Q24W) for approximately 144 weeks in participants with neovascular age-related macular degeneration (nAMD) who have completed either Phase II Study GX28228 (Ladder) or Phase III Study GR40548 (Archway).

Clinical Study Identifier: NCT03683251

Find a site near you

Start Over

Palmetto Retina Center

Florence, SC United States
  Connect »